These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8085374)

  • 1. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.
    López MC; Silva Y; Thomas MC; Garcia A; Faus MJ; Alonso P; Martinez F; Del Real G; Alonso C
    Vaccine; 1994 May; 12(7):585-91. PubMed ID: 8085374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
    Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission.
    Teuscher T; Schellenberg JR; Bastos de Azevedo I; Hurt N; Smith T; Hayes R; Masanja H; Silva Y; Lopez MC; Kitua A
    Vaccine; 1994 Mar; 12(4):328-36. PubMed ID: 8178555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
    Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
    Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of context and adjuvant on the immunogenicity of recombinant proteins and peptide conjugates derived from the polymorphic malarial surface antigen MSA2.
    Jones GL; Spencer L; Lord R; Saul AJ
    Vaccine; 1996 Jan; 14(1):77-84. PubMed ID: 8821653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design.
    Alonso PL; Tanner M; Smith T; Hayes RJ; Schellenberg JA; Lopez MC; Bastos de Azevedo I; Menendez C; Lyimo E; Weiss N
    Vaccine; 1994 Feb; 12(2):181-6. PubMed ID: 8147101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66.
    Haywood M; Conway DJ; Weiss H; Metzger W; D'Alessandro U; Snounou G; Targett G; Greenwood B
    Trans R Soc Trop Med Hyg; 1999 Feb; 93 Suppl 1():65-8. PubMed ID: 10450429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.
    Alonso PL; Smith T; Schellenberg JR; Masanja H; Mwankusye S; Urassa H; Bastos de Azevedo I; Chongela J; Kobero S; Menendez C
    Lancet; 1994 Oct; 344(8931):1175-81. PubMed ID: 7934537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
    Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
    Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group.
    Nosten F; Luxemburger C; Kyle DE; Ballou WR; Wittes J; Wah E; Chongsuphajaisiddhi T; Gordon DM; White NJ; Sadoff JC; Heppner DG
    Lancet; 1996 Sep; 348(9029):701-7. PubMed ID: 8806288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for antibody recognition of the NANP repeats in
    Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The investigational vaccine SPf66 against Plasmodium falciparum: myth or reality?].
    Robert F; Gazin P
    Sante; 1996; 6(1):56-7. PubMed ID: 8612015
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
    Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
    Nardin EH; Oliveira GA; Calvo-Calle JM; Wetzel K; Maier C; Birkett AJ; Sarpotdar P; Corado ML; Thornton GB; Schmidt A
    Infect Immun; 2004 Nov; 72(11):6519-27. PubMed ID: 15501783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation.
    Faber BW; Hellwig S; Houard S; Havelange N; Drossard J; Mertens H; Croon A; Kastilan R; Byrne R; van der Werff N; van der Eijk M; Thomas AW; Kocken CH; Remarque EJ
    PLoS One; 2016; 11(10):e0164053. PubMed ID: 27695087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.